209 related articles for article (PubMed ID: 34778306)
21. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.
Hsu DK; Dowling CA; Jeng KC; Chen JT; Yang RY; Liu FT
Int J Cancer; 1999 May; 81(4):519-26. PubMed ID: 10225438
[TBL] [Abstract][Full Text] [Related]
22. Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis.
Gong M; Cheung A; Wang QS; Li G; Goudis CA; Bazoukis G; Lip GYH; Baranchuk A; Korantzopoulos P; Letsas KP; Tse G; Liu T
J Clin Lab Anal; 2020 Mar; 34(3):e23104. PubMed ID: 31917884
[TBL] [Abstract][Full Text] [Related]
23. Galectin-3 in chronic kidney disease.
Bellos I; Marinaki S; Lagiou P; Benetou V
Clin Chim Acta; 2024 Jun; 559():119727. PubMed ID: 38750780
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-Analysis.
Ramos-Martínez JC; Altamirano-Gómez G; Ramos-Martínez I; Valencia J; Hernández-Zimbrón L; Hernández-Juárez J; Echeverría-Vásquez P; Hernández-González LL; Pérez-Campos E; Pérez-Campos Mayoral L; Ramos-Martínez E
Clin Breast Cancer; 2022 Jul; 22(5):399-409. PubMed ID: 35058144
[TBL] [Abstract][Full Text] [Related]
25. Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis.
Zhou X; Sun L; Jing D; Xu G; Zhang J; Lin L; Zhao J; Yao Z; Lin H
Front Physiol; 2018; 9():452. PubMed ID: 29765332
[No Abstract] [Full Text] [Related]
26. Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma.
Tan RZH; Lockart I; Abdel Shaheed C; Danta M
Aliment Pharmacol Ther; 2021 Aug; 54(4):356-367. PubMed ID: 34247393
[TBL] [Abstract][Full Text] [Related]
27. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.
Kim NJ; Vutien P; Cleveland E; Cravero A; Ioannou GN
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1723-1738.e5. PubMed ID: 35525392
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma.
Setayesh T; Colquhoun SD; Wan YY
Liver Res; 2020 Dec; 4(4):173-179. PubMed ID: 34567824
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis.
Shakiba E; Ramezani M; Sadeghi M
Clin Exp Hepatol; 2018 Sep; 4(3):182-190. PubMed ID: 30324143
[TBL] [Abstract][Full Text] [Related]
30. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
31. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Laparoscopic Hepatectomy
Pan Y; Xia S; Cai J; Chen K; Cai X
Front Oncol; 2021; 11():652272. PubMed ID: 34026628
[TBL] [Abstract][Full Text] [Related]
33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
34. Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study.
Zhang C; Wu J; Xu J; Xu J; Xian J; Xue S; Ye J
Dis Markers; 2019; 2019():2046825. PubMed ID: 31814857
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of galectin-3 in chronic kidney disease patients: a systematic review and meta-analysis.
Zhang T; Cao S; Yang H; Li J
Int Urol Nephrol; 2019 Jun; 51(6):1005-1011. PubMed ID: 30963453
[TBL] [Abstract][Full Text] [Related]
36. [Serum and tissue expressions of galectin-3 in hepatocellular carcinoma and the clinical significances].
Fang QQ; Ni RZ; Xiao MB; Jiang F; Lu CH
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):527-31. PubMed ID: 22152245
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development.
Nassar ES; Elkalbashawy YA; Kamal A; Zakaria NHE
Clin Exp Hepatol; 2021 Mar; 7(1):74-78. PubMed ID: 34027118
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis of evaluation of serum interleukin 8 levels in hepatocellular carcinoma.
Shakiba E; Sadeghi M; Shakiba M
Clin Exp Hepatol; 2019 May; 5(2):123-128. PubMed ID: 31508492
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis.
Zhou ZY; Liu SR; Xu LB; Liu C; Zhang R
J Clin Transl Hepatol; 2021 Dec; 9(6):889-897. PubMed ID: 34966652
[TBL] [Abstract][Full Text] [Related]
40. Therapy of experimental NASH and fibrosis with galectin inhibitors.
Traber PG; Zomer E
PLoS One; 2013; 8(12):e83481. PubMed ID: 24367597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
